November 1, 2010 @ 5:00 p.m. ET | #LB-2 “Telaprevir in Combination with Peginterferon Alfa2a and Ribavirin for 24 or 48 weeks in Treatment-Naïve Genotype 1 HCV Patients who Achieved an Extended Rapid Viral Response: Final Results of Phase 3 ILLUMINATE Study” Hynes Auditorium |
November 2, 2010 @ 8:00 a.m. ET | #211 “Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naïve Patients: Final Results of Phase 3 ADVANCE Study” Hynes Auditorium |
November 2, 2010 @ 11:45 a.m. ET | #227 “Long-term Follow-up of Patients with Chronic Hepatitis C Treated with Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin: Interim Analysis of the EXTEND Study” Hynes Room 304/306 |
October 31, 2010 @ 8:00 a.m. ET | #805 “No Impact of Insulin Resistance on Antiviral Efficacy of Telaprevir-based Regimen in HCV Genotype 1 Treatment-Naïve Patients: Subanalysis of C208 Study” Hynes Exhibit Hall C |
| #828 “Activity of Telaprevir Monotherapy or in Combination with Peginterferon-alfa-2a and Ribavirin in Treatment-naïve Genotype 4 Hepatitis-C Patients: Final Results of Study C210” Hynes Exhibit Hall C |
| #1051 “Spontaneous Viral Clearance in a Patient With Chronic Hepatitis C who Relapsed After Telaprevir-based Treatment” Hynes Exhibit Hall C |
| #899 “The Effect of Hepatitis C Treatment Response on Medical Costs: a 5-Year Longitudinal Analysis in a Managed Care Setting” Hynes Exhibit Hall C |
November 1, 2010 @ 8:00 a.m. ET | #LB-11 “Clinical Virology Results from Telaprevir Phase 3 Study ADVANCE” Hynes Exhibit Hall C |
No comments:
Post a Comment